#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Ph negative myeloproliferative neoplasms in Czech haematological centres – MIND analysis


Authors: N. Podstavková 1;  B. Weinbergerová 1;  M. Palová 2;  A. Hluší 2;  P. Bělohlávková 3;  M. Brejcha 4;  L. Stejskal 5;  Z. Křístková 6;  T. Nečasová 6;  K. Hurdálková 6;  A. Panovská 1;  Y. Brychtová 1;  L. Červinek 1;  M. Horáčková 1;  Z. Král 1;  P. Žák 3;  E. Faber 2;  M. Doubek 1;  J. Mayer 1
Authors‘ workplace: Interní hematologická a onkologická klinika LF MU a FN Brno 1;  Hemato-onkologická klinika LF UP a FN Olomouc 2;  4. Interní hematologická klinika LF UK a FN Hradec Králové 3;  Komplexní onkologické centrum Nový Jičín 4;  Klinika hematoonkologie LF OU a FN Ostrava 5;  Institut bio­statistiky a analýz s. r. o., spin-off společnost MU Brno 6
Published in: Transfuze Hematol. dnes,27, 2021, No. 3, p. 242-253.
Category: Original Papers
doi: https://doi.org/10.48095/cctahd2021242

Overview

Background: Our MIND database was initiated on May 1, 2013, with the primary objective of collecting data from patients with Ph negative myeloproliferative neoplasms (Ph-MPN) in Czech haematological centres. The principal aim was to analyse and compare our patient data with published data. Patients and Methods: A total of 641 valid Ph-MPN patients registered in MIND were analysed from 2013 to 2020. Epidemiology, dia­gnostics, therapy and prognosis were evaluated. Results: With a 35-month median follow-up, the most common dia­gnosis was polycythaemia vera- PV (34%) followed by primary myelofibrosis, PMF (31%) and essential thrombocythemia, ET (22%). At the time of dia­gnosis, patients suffered mostly from fatigue (52%), night sweats (32%), weakness (30%) and itching (27%). Splenomegaly occurred in more than half of PMF patients (54%). The JAK2 V617F mutation was present in 90% of PV, 65% of PMF and 62% of ET, respectively. The CALR mutation was found in 22% of ET and 16% of PMF, respectively. Cytogenetic abnormalities were significantly more frequently documented in both PMF and PV compared to ET (17 and 15 vs. 3% of examined patients, respectively; P ≤ 0.005). Thrombosis (22%) and bleeding (10%) were the most common complications at dia­gnosis with no significant difference in frequency among PV, ET, and PMF, respectively (P > 0.017). In PV, hydroxyurea was the most frequently used drug as both 1st and 2nd line treatment (72 and 65%, respectively). Anagrelide was used in both lines in ET (52 and 82%, respectively) and hydroxyurea was used as 1st line treatment with ruxolitinib as 2nd line treatment in PMF (70 and 30%, respectively). Leukemic transformation was detected in 3% of Ph-MPN and only in MF (10%). 17% of our patients died, most from PMF (53%). Median overall survival was not attained in ET, contrasting with the lowest median in secondary MF (2.5 years). In PMF, median overall survival was decreased by dotage, higher IPSS, and JAK2 V617F mutation presence. Conclusion: We have recognized a recurring definitive frequency of symptoms that exacerbate patient quality of life. A higher incidence of additional cytogenetic abnormalities was recorded more frequently with both PMF and PV compared to ET. During dia­gnosis, thrombotic and bleeding events were present with no significant difference in frequency among PV, ET, and PMF. Overall survival median was the longest in PV, compared to MF with the most frequent leukemic transformations and the lowest survival. In PMF, higher age, higher IPSS and JAK2 V617F presence were shown as factors shortening survival.


Sources
  1. Titmarsh GJ, Duncombe AS, McMullin MF, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014 Jun; 89 (6): 581–587.
  2. Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 2015; 1 (1): 97–105.
  3. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127 (20): 2391–2405.
  4. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434 (7037): 1144–1148.
  5. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352 (17): 1779–1790.
  6. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013; 27: 1861–1869.
  7. Tefferi, A. Myeloproliferative neoplasms: A decade of discoveries and treatment advances. Am J Hematol. 2016; 91: 50–58.
  8. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014; 124 (16): 2507–2513.
  9. Grinfeld J, Nangalia J, Baxter EJ, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018; 379 (15): 1416–1430.
  10. Dunbar AJ, Rampal RK, Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood. 2020; 136 (1): 61–70.
  11. https: //cell-sal-mind.data-warehouse.zone/login
  12. Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013; 121 (23): 4778–4781.
  13. Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013; 122 (8): 1395–1398.
  14. 14.https: //ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf
  15. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012; 30 (33): 4098–4103.
  16. EuroQoL Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990; 16: 199–208.
  17. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005; 90 (8): 1128–1132.
  18. Barbui T, Barosi G, Birgegard G, et al. European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011; 29 (6): 761–770.
  19. Barbui T, Finazzi G, Carobbio­ A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012; 120 (26): 5128–5133.
  20. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009; 113 (13): 2895–2901.
  21. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010; 1159: 1703–1708.
  22. Srour SA, Devesa SS, Morton LM, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12. Br J Haematol. 2016; 174 (3): 382–396.
  23. Shallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Rev. 2020; 42: 100706.
  24. Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014; 92 (4): 289–297.
  25. Harrison CN, Koschmieder S, Foltz L, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol. 2017; 96 (10): 1653–1665.
  26. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014; 28 (7): 1472–1477.
  27. Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70+ version 2.0: mutation and karyotype‐enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018; 36: 1769–1770.
  28. Tefferi A, Guglielmelli P, Nicolosi M, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018; 32: 1631–1642.
  29. Kaifie, A., Kirschner, M., Wolf, D. et al. Bleed­ing, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol. 2016; 9: 18.
  30. Rungjirajittranon T, Owattanapanich W, Ungprasert P, Siritanaratkul N, Ruchutrakool T. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at dia­gnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer. 2019; 19 (1): 184.
  31. Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018; 32 (5): 1057–1069.
  32. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005; 353 (1): 33–45.
  33. Hultcrantz M, Kristinsson SY, Andersson TM, et al. Patterns of survival among patients with myeloproliferative neoplasms dia­gnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012; 30 (24): 2995–3001.
  34. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013; 27 (9): 1874–1881.
  35. Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at dia­gnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012; 120 (6): 1197–1201.
  36. Bonicelli G, Abdulkarim K, Mounier M, et al. Leucocytosis and thrombosis at dia­gnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients. Br J Haematol. 2013; 160 (2): 251–254.
  37. Weinbergerová B, Čičátková P, Palová M, et al. Zkušenosti s léčbou ruxolitinibem u pacientu s myelofibrózou a pravou polycytemií na českých hematologických pracovištích. Transfuze Hematol Dnes. 2017; 23 (1): 30–40.
  38. Weinbergerová B, Bělohlávková P, Ráčil Z, Mayer J. Ph (BCR-ABL1) -negativní myeloproliferativní neoplázie (D45, D47.1, D47.3). In: Léčebné postupy v hematologii. Doporučení ČHS ČLS JEP. 2016: 153–178.
  39. Czech J, Cordua S, Weinbergerova B, et al. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-alpha via JAK1/STAT1 activation. Leukemia. 2019; 33 (4): 995–1010.
Labels
Haematology Internal medicine Clinical oncology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#